General principles and pharmacology of biologics in inflammatory bowel disease.
The pharmacology of each biologic agent is important regarding the dose required to achieve benefits, duration of therapeutic effect, and the induction of immunogenicity. Comprehension of the individual pharmacology, pharmacodynamics, and pharmacokinetics, in addition to the impact of concomitant immunomodulation on immunogenicity allows optimization of each biologic agent in the appropriate inductive or maintenance setting of IBD.
Kozuch
Patricia L
PL
Division of Gastroenterology, Department of Medicine, University of Chicago Hospitals, MC 4076, 5841 South Maryland Avenue, Chicago, IL 60637, USA.
Hanauer
Stephen B
SB
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products / Q000494:pharmacology* / Q000627:therapeutic use; D015815:Cell Adhesion Molecules / Q000037:antagonists & inhibitors; D000068582:Certolizumab Pegol; D005765:Gastrointestinal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007140:Immunoglobulin Fab Fragments; D015212:Inflammatory Bowel Diseases / Q000473:pathology / Q000628:therapy*; D000069285:Infliximab; D000069442:Natalizumab; D011092:Polyethylene Glycols / Q000494:pharmacology / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D015815:Cell Adhesion Molecules; D005765:Gastrointestinal Agents; D007140:Immunoglobulin Fab Fragments; C501380:MLN02 antibody, human; D000069442:Natalizumab; D014409:Tumor Necrosis Factor-alpha; D011092:Polyethylene Glycols; D000069285:Infliximab; D000068879:Adalimumab; C456519:visilizumab; D000068582:Certolizumab Pegol